nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—SLC31A1—Cisplatin—hematologic cancer	0.0704	0.147	CbGbCtD
Bortezomib—CYP1A2—Anagrelide—hematologic cancer	0.0174	0.0362	CbGbCtD
Bortezomib—CYP1A1—Methoxsalen—hematologic cancer	0.0174	0.0362	CbGbCtD
Bortezomib—CYP1A1—Daunorubicin—hematologic cancer	0.0158	0.0329	CbGbCtD
Bortezomib—PTGS1—Thalidomide—hematologic cancer	0.0144	0.03	CbGbCtD
Bortezomib—CYP1A1—Thalidomide—hematologic cancer	0.0144	0.03	CbGbCtD
Bortezomib—PTGS1—Ifosfamide—hematologic cancer	0.0127	0.0264	CbGbCtD
Bortezomib—CYP1A1—Dacarbazine—hematologic cancer	0.0124	0.0258	CbGbCtD
Bortezomib—PTGS1—Imatinib—hematologic cancer	0.0121	0.0252	CbGbCtD
Bortezomib—CYP2C9—Bexarotene—hematologic cancer	0.0109	0.0226	CbGbCtD
Bortezomib—CYP1A1—Dasatinib—hematologic cancer	0.00973	0.0203	CbGbCtD
Bortezomib—CYP2D6—Lomustine—hematologic cancer	0.00923	0.0192	CbGbCtD
Bortezomib—CYP1A2—Carmustine—hematologic cancer	0.00913	0.019	CbGbCtD
Bortezomib—CYP2C9—Idarubicin—hematologic cancer	0.00899	0.0187	CbGbCtD
Bortezomib—CYP2D6—Idarubicin—hematologic cancer	0.00822	0.0171	CbGbCtD
Bortezomib—CYP1A2—Methoxsalen—hematologic cancer	0.00776	0.0162	CbGbCtD
Bortezomib—CYP2C8—Ifosfamide—hematologic cancer	0.00731	0.0152	CbGbCtD
Bortezomib—CYP1A2—Daunorubicin—hematologic cancer	0.00706	0.0147	CbGbCtD
Bortezomib—CYP2D6—Hydroxyurea—hematologic cancer	0.00699	0.0146	CbGbCtD
Bortezomib—CYP2C19—Thalidomide—hematologic cancer	0.00697	0.0145	CbGbCtD
Bortezomib—CYP1A2—Alitretinoin—hematologic cancer	0.00692	0.0144	CbGbCtD
Bortezomib—CYP2C19—Teniposide—hematologic cancer	0.00665	0.0139	CbGbCtD
Bortezomib—CYP1A2—Thalidomide—hematologic cancer	0.00643	0.0134	CbGbCtD
Bortezomib—CYP2C8—Nilotinib—hematologic cancer	0.00635	0.0132	CbGbCtD
Bortezomib—CYP3A4—Bexarotene—hematologic cancer	0.00631	0.0131	CbGbCtD
Bortezomib—CYP2C19—Ifosfamide—hematologic cancer	0.00614	0.0128	CbGbCtD
Bortezomib—PTGS1—Etoposide—hematologic cancer	0.00606	0.0126	CbGbCtD
Bortezomib—CYP3A4—Lomustine—hematologic cancer	0.00587	0.0122	CbGbCtD
Bortezomib—CYP3A4—Busulfan—hematologic cancer	0.00587	0.0122	CbGbCtD
Bortezomib—CYP2C19—Imatinib—hematologic cancer	0.00586	0.0122	CbGbCtD
Bortezomib—CYP2C9—Thalidomide—hematologic cancer	0.0058	0.0121	CbGbCtD
Bortezomib—CYP1A2—Dacarbazine—hematologic cancer	0.00553	0.0115	CbGbCtD
Bortezomib—CYP2C9—Teniposide—hematologic cancer	0.00553	0.0115	CbGbCtD
Bortezomib—CYP1A2—Imatinib—hematologic cancer	0.00541	0.0113	CbGbCtD
Bortezomib—CYP3A4—Thiotepa—hematologic cancer	0.00523	0.0109	CbGbCtD
Bortezomib—CYP2C9—Ifosfamide—hematologic cancer	0.0051	0.0106	CbGbCtD
Bortezomib—CYP1A1—Dexamethasone—hematologic cancer	0.00498	0.0104	CbGbCtD
Bortezomib—CYP2C9—Imatinib—hematologic cancer	0.00487	0.0102	CbGbCtD
Bortezomib—CYP2D6—Imatinib—hematologic cancer	0.00446	0.00928	CbGbCtD
Bortezomib—CYP2C9—Nilotinib—hematologic cancer	0.00443	0.00923	CbGbCtD
Bortezomib—CYP1A2—Dasatinib—hematologic cancer	0.00434	0.00905	CbGbCtD
Bortezomib—CYP3A4—Methoxsalen—hematologic cancer	0.00407	0.00847	CbGbCtD
Bortezomib—CYP2D6—Nilotinib—hematologic cancer	0.00405	0.00844	CbGbCtD
Bortezomib—CYP2D6—Vinorelbine—hematologic cancer	0.00402	0.00837	CbGbCtD
Bortezomib—CYP2C19—Prednisone—hematologic cancer	0.00386	0.00805	CbGbCtD
Bortezomib—CYP3A4—Daunorubicin—hematologic cancer	0.0037	0.00771	CbGbCtD
Bortezomib—CYP2C8—Etoposide—hematologic cancer	0.0035	0.00728	CbGbCtD
Bortezomib—CYP3A4—Cytarabine—hematologic cancer	0.00326	0.0068	CbGbCtD
Bortezomib—CYP3A4—Teniposide—hematologic cancer	0.00321	0.0067	CbGbCtD
Bortezomib—CYP3A4—Ifosfamide—hematologic cancer	0.00297	0.00618	CbGbCtD
Bortezomib—CTSG—hematopoietic system—hematologic cancer	0.00296	0.0382	CbGeAlD
Bortezomib—CYP2C8—Dexamethasone—hematologic cancer	0.00287	0.00599	CbGbCtD
Bortezomib—PSMA1—hematopoietic system—hematologic cancer	0.00284	0.0367	CbGeAlD
Bortezomib—CYP3A4—Imatinib—hematologic cancer	0.00283	0.0059	CbGbCtD
Bortezomib—CYP1A2—Etoposide—hematologic cancer	0.00271	0.00564	CbGbCtD
Bortezomib—CYP3A4—Ruxolitinib—hematologic cancer	0.00267	0.00556	CbGbCtD
Bortezomib—CYP3A4—Nilotinib—hematologic cancer	0.00258	0.00537	CbGbCtD
Bortezomib—CYP3A4—Vinorelbine—hematologic cancer	0.00255	0.00532	CbGbCtD
Bortezomib—CYP2C9—Cisplatin—hematologic cancer	0.00248	0.00517	CbGbCtD
Bortezomib—CYP2D6—Vinblastine—hematologic cancer	0.00247	0.00516	CbGbCtD
Bortezomib—CYP2C19—Dexamethasone—hematologic cancer	0.00241	0.00502	CbGbCtD
Bortezomib—CYP3A4—Triamcinolone—hematologic cancer	0.00234	0.00487	CbGbCtD
Bortezomib—CYP3A4—Dasatinib—hematologic cancer	0.00228	0.00474	CbGbCtD
Bortezomib—CYP3A4—Mitoxantrone—hematologic cancer	0.00225	0.00468	CbGbCtD
Bortezomib—PSMA1—gonad—hematologic cancer	0.00216	0.0279	CbGeAlD
Bortezomib—PSMD2—hematopoietic system—hematologic cancer	0.00211	0.0273	CbGeAlD
Bortezomib—CYP2C9—Dexamethasone—hematologic cancer	0.002	0.00418	CbGbCtD
Bortezomib—CYP3A4—Betamethasone—hematologic cancer	0.002	0.00417	CbGbCtD
Bortezomib—CYP3A4—Prednisolone—hematologic cancer	0.00198	0.00412	CbGbCtD
Bortezomib—CTSG—blood—hematologic cancer	0.00196	0.0253	CbGeAlD
Bortezomib—CTSG—bone marrow—hematologic cancer	0.0019	0.0245	CbGeAlD
Bortezomib—CYP3A4—Prednisone—hematologic cancer	0.00187	0.00389	CbGbCtD
Bortezomib—CYP2D6—Dexamethasone—hematologic cancer	0.00183	0.00382	CbGbCtD
Bortezomib—PSMA1—bone marrow—hematologic cancer	0.00182	0.0235	CbGeAlD
Bortezomib—CYP3A4—Irinotecan—hematologic cancer	0.00177	0.00369	CbGbCtD
Bortezomib—CTSG—lung—hematologic cancer	0.00172	0.0222	CbGeAlD
Bortezomib—PSMA1—lung—hematologic cancer	0.00165	0.0213	CbGeAlD
Bortezomib—CTSG—testis—hematologic cancer	0.00162	0.0209	CbGeAlD
Bortezomib—PSMB1—hematopoietic system—hematologic cancer	0.00162	0.0209	CbGeAlD
Bortezomib—PSMD2—gonad—hematologic cancer	0.00161	0.0207	CbGeAlD
Bortezomib—PSMB2—hematopoietic system—hematologic cancer	0.00158	0.0204	CbGeAlD
Bortezomib—PSMD1—blood—hematologic cancer	0.00158	0.0204	CbGeAlD
Bortezomib—CYP3A4—Vinblastine—hematologic cancer	0.00157	0.00328	CbGbCtD
Bortezomib—PSMA1—testis—hematologic cancer	0.00156	0.0201	CbGeAlD
Bortezomib—CYP3A4—Vincristine—hematologic cancer	0.00155	0.00322	CbGbCtD
Bortezomib—PSMD1—bone marrow—hematologic cancer	0.00153	0.0197	CbGeAlD
Bortezomib—CYP2D6—Doxorubicin—hematologic cancer	0.00152	0.00317	CbGbCtD
Bortezomib—CYP3A4—Etoposide—hematologic cancer	0.00142	0.00295	CbGbCtD
Bortezomib—PSMD2—blood—hematologic cancer	0.0014	0.0181	CbGeAlD
Bortezomib—PSMB8—blood—hematologic cancer	0.00139	0.018	CbGeAlD
Bortezomib—PSMD1—lung—hematologic cancer	0.00139	0.0179	CbGeAlD
Bortezomib—PSMD2—bone marrow—hematologic cancer	0.00135	0.0175	CbGeAlD
Bortezomib—PSMB8—bone marrow—hematologic cancer	0.00135	0.0174	CbGeAlD
Bortezomib—PSMD1—testis—hematologic cancer	0.00131	0.0169	CbGeAlD
Bortezomib—PSMB1—gonad—hematologic cancer	0.00123	0.0159	CbGeAlD
Bortezomib—PSMB5—blood—hematologic cancer	0.00123	0.0159	CbGeAlD
Bortezomib—PSMD2—lung—hematologic cancer	0.00123	0.0158	CbGeAlD
Bortezomib—PSMB8—lung—hematologic cancer	0.00122	0.0157	CbGeAlD
Bortezomib—PSMB2—gonad—hematologic cancer	0.0012	0.0155	CbGeAlD
Bortezomib—PSMB5—bone marrow—hematologic cancer	0.00119	0.0154	CbGeAlD
Bortezomib—CTSG—lymph node—hematologic cancer	0.00118	0.0152	CbGeAlD
Bortezomib—CYP3A4—Dexamethasone—hematologic cancer	0.00117	0.00243	CbGbCtD
Bortezomib—PSMD2—testis—hematologic cancer	0.00116	0.0149	CbGeAlD
Bortezomib—PSMB8—testis—hematologic cancer	0.00115	0.0149	CbGeAlD
Bortezomib—PSMA1—lymph node—hematologic cancer	0.00113	0.0146	CbGeAlD
Bortezomib—PSMB5—lung—hematologic cancer	0.00108	0.0139	CbGeAlD
Bortezomib—PSMB1—blood—hematologic cancer	0.00107	0.0139	CbGeAlD
Bortezomib—PSMB2—blood—hematologic cancer	0.00105	0.0135	CbGeAlD
Bortezomib—SLC31A1—gonad—hematologic cancer	0.00104	0.0134	CbGeAlD
Bortezomib—PSMB1—bone marrow—hematologic cancer	0.00104	0.0134	CbGeAlD
Bortezomib—PSMB5—testis—hematologic cancer	0.00102	0.0131	CbGeAlD
Bortezomib—PSMB2—bone marrow—hematologic cancer	0.00101	0.0131	CbGeAlD
Bortezomib—CYP3A4—Doxorubicin—hematologic cancer	0.000967	0.00201	CbGbCtD
Bortezomib—PSMD1—lymph node—hematologic cancer	0.000947	0.0122	CbGeAlD
Bortezomib—PSMB1—lung—hematologic cancer	0.000942	0.0122	CbGeAlD
Bortezomib—PSMB2—lung—hematologic cancer	0.000919	0.0119	CbGeAlD
Bortezomib—SLC31A1—blood—hematologic cancer	0.000908	0.0117	CbGeAlD
Bortezomib—PSMB1—testis—hematologic cancer	0.000889	0.0115	CbGeAlD
Bortezomib—SLC31A1—bone marrow—hematologic cancer	0.000878	0.0113	CbGeAlD
Bortezomib—PSMB2—testis—hematologic cancer	0.000867	0.0112	CbGeAlD
Bortezomib—PSMD2—lymph node—hematologic cancer	0.000839	0.0108	CbGeAlD
Bortezomib—PSMB8—lymph node—hematologic cancer	0.000834	0.0108	CbGeAlD
Bortezomib—SLC31A1—lung—hematologic cancer	0.000796	0.0103	CbGeAlD
Bortezomib—SLC31A1—testis—hematologic cancer	0.000751	0.00969	CbGeAlD
Bortezomib—PSMB5—lymph node—hematologic cancer	0.000737	0.00951	CbGeAlD
Bortezomib—PSMB1—lymph node—hematologic cancer	0.000644	0.00832	CbGeAlD
Bortezomib—PSMB2—lymph node—hematologic cancer	0.000628	0.00811	CbGeAlD
Bortezomib—CYP2C19—hematopoietic system—hematologic cancer	0.000578	0.00746	CbGeAlD
Bortezomib—SLC31A1—lymph node—hematologic cancer	0.000544	0.00703	CbGeAlD
Bortezomib—CYP2C8—hematopoietic system—hematologic cancer	0.000504	0.00651	CbGeAlD
Bortezomib—CYP1A2—hematopoietic system—hematologic cancer	0.000472	0.00609	CbGeAlD
Bortezomib—CYP1A1—hematopoietic system—hematologic cancer	0.000465	0.00601	CbGeAlD
Bortezomib—CYP2C9—hematopoietic system—hematologic cancer	0.000448	0.00578	CbGeAlD
Bortezomib—PSMB8—Ponatinib—Nilotinib—hematologic cancer	0.000418	0.11	CbGdCrCtD
Bortezomib—PTGS1—hematopoietic system—hematologic cancer	0.000409	0.00528	CbGeAlD
Bortezomib—CYP2C19—blood—hematologic cancer	0.000383	0.00494	CbGeAlD
Bortezomib—CYP3A4—hematopoietic system—hematologic cancer	0.000341	0.00441	CbGeAlD
Bortezomib—CYP2D6—hematopoietic system—hematologic cancer	0.000336	0.00434	CbGeAlD
Bortezomib—CYP2C8—blood—hematologic cancer	0.000334	0.00431	CbGeAlD
Bortezomib—Lacosamide—CA9—hematologic cancer	0.000321	0.825	CrCbGaD
Bortezomib—PSMB8—Ponatinib—Imatinib—hematologic cancer	0.000317	0.0833	CbGdCrCtD
Bortezomib—CYP1A2—blood—hematologic cancer	0.000313	0.00403	CbGeAlD
Bortezomib—CYP1A1—blood—hematologic cancer	0.000308	0.00398	CbGeAlD
Bortezomib—CYP2C9—blood—hematologic cancer	0.000297	0.00383	CbGeAlD
Bortezomib—CYP2C8—testis—hematologic cancer	0.000276	0.00357	CbGeAlD
Bortezomib—CYP1A2—lung—hematologic cancer	0.000274	0.00354	CbGeAlD
Bortezomib—PTGS1—blood—hematologic cancer	0.000271	0.0035	CbGeAlD
Bortezomib—CYP1A1—lung—hematologic cancer	0.00027	0.00349	CbGeAlD
Bortezomib—PSMB2—Azacitidine—Pentostatin—hematologic cancer	0.000246	0.0648	CbGdCrCtD
Bortezomib—PTGS1—lung—hematologic cancer	0.000237	0.00307	CbGeAlD
Bortezomib—PSMB8—Podofilox—Teniposide—hematologic cancer	0.000228	0.0598	CbGdCrCtD
Bortezomib—CYP3A4—blood—hematologic cancer	0.000226	0.00292	CbGeAlD
Bortezomib—PTGS1—testis—hematologic cancer	0.000224	0.00289	CbGeAlD
Bortezomib—CYP2D6—blood—hematologic cancer	0.000223	0.00287	CbGeAlD
Bortezomib—PSMB2—Azacitidine—Clofarabine—hematologic cancer	0.00022	0.0578	CbGdCrCtD
Bortezomib—PSMB2—Azacitidine—Nelarabine—hematologic cancer	0.000206	0.0543	CbGdCrCtD
Bortezomib—CYP1A1—lymph node—hematologic cancer	0.000185	0.00239	CbGeAlD
Bortezomib—CYP2D6—testis—hematologic cancer	0.000184	0.00238	CbGeAlD
Bortezomib—PTGS1—lymph node—hematologic cancer	0.000162	0.0021	CbGeAlD
Bortezomib—PSMB2—Azacitidine—Fludarabine—hematologic cancer	0.000161	0.0424	CbGdCrCtD
Bortezomib—PSMB2—Azacitidine—Cytarabine—hematologic cancer	0.000152	0.04	CbGdCrCtD
Bortezomib—PSMB2—Azacitidine—Gemcitabine—hematologic cancer	0.000152	0.04	CbGdCrCtD
Bortezomib—PSMB2—Azacitidine—Cladribine—hematologic cancer	0.000148	0.039	CbGdCrCtD
Bortezomib—PSMB8—Vincristine—Vinorelbine—hematologic cancer	0.000145	0.0381	CbGdCrCtD
Bortezomib—PSMB8—Vinorelbine—Vincristine—hematologic cancer	0.000135	0.0356	CbGdCrCtD
Bortezomib—PSMB8—Vinorelbine—Vinblastine—hematologic cancer	0.000135	0.0356	CbGdCrCtD
Bortezomib—PSMB8—Podofilox—Etoposide—hematologic cancer	0.000135	0.0356	CbGdCrCtD
Bortezomib—PSMB8—Vincristine—Vinblastine—hematologic cancer	0.000116	0.0305	CbGdCrCtD
Bortezomib—Nateglinide—ALB—hematologic cancer	6.81e-05	0.175	CrCbGaD
Bortezomib—PSMD2—Fluticasone Propionate—Dexamethasone—hematologic cancer	5.52e-05	0.0145	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Betamethasone—hematologic cancer	5.52e-05	0.0145	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Triamcinolone—hematologic cancer	5.39e-05	0.0142	CbGdCrCtD
Bortezomib—PSMB8—Medrysone—Prednisolone—hematologic cancer	4.97e-05	0.0131	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Betamethasone—hematologic cancer	3.97e-05	0.0104	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Dexamethasone—hematologic cancer	3.97e-05	0.0104	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Triamcinolone—hematologic cancer	3.88e-05	0.0102	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Prednisone—hematologic cancer	3.68e-05	0.00969	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Prednisolone—hematologic cancer	3.6e-05	0.00946	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Betamethasone—hematologic cancer	3.03e-05	0.00796	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Dexamethasone—hematologic cancer	3.03e-05	0.00796	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Triamcinolone—hematologic cancer	2.96e-05	0.00777	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Prednisone—hematologic cancer	2.81e-05	0.00738	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Betamethasone—hematologic cancer	2.8e-05	0.00735	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Dexamethasone—hematologic cancer	2.8e-05	0.00735	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Prednisolone—hematologic cancer	2.74e-05	0.0072	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Triamcinolone—hematologic cancer	2.73e-05	0.00719	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Triamcinolone—hematologic cancer	2.73e-05	0.00719	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Prednisone—hematologic cancer	2.59e-05	0.00682	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Prednisone—hematologic cancer	2.59e-05	0.00682	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Prednisolone—hematologic cancer	2.53e-05	0.00666	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Prednisolone—hematologic cancer	2.53e-05	0.00666	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Dexamethasone—hematologic cancer	1.62e-05	0.00427	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Betamethasone—hematologic cancer	1.62e-05	0.00427	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Triamcinolone—hematologic cancer	1.59e-05	0.00417	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Triamcinolone—hematologic cancer	1.59e-05	0.00417	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Prednisone—hematologic cancer	1.5e-05	0.00396	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Prednisone—hematologic cancer	1.5e-05	0.00396	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Prednisolone—hematologic cancer	1.47e-05	0.00386	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Prednisolone—hematologic cancer	1.47e-05	0.00386	CbGdCrCtD
Bortezomib—Diarrhoea—Etoposide—hematologic cancer	6.84e-06	2.52e-05	CcSEcCtD
Bortezomib—Anorexia—Prednisone—hematologic cancer	6.83e-06	2.52e-05	CcSEcCtD
Bortezomib—Eye disorder—Doxorubicin—hematologic cancer	6.82e-06	2.51e-05	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—hematologic cancer	6.81e-06	2.51e-05	CcSEcCtD
Bortezomib—Tinnitus—Doxorubicin—hematologic cancer	6.81e-06	2.51e-05	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—hematologic cancer	6.78e-06	2.5e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Dexamethasone—hematologic cancer	6.78e-06	2.5e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Betamethasone—hematologic cancer	6.78e-06	2.5e-05	CcSEcCtD
Bortezomib—Flushing—Doxorubicin—hematologic cancer	6.78e-06	2.49e-05	CcSEcCtD
Bortezomib—Cardiac disorder—Doxorubicin—hematologic cancer	6.78e-06	2.49e-05	CcSEcCtD
Bortezomib—Flatulence—Epirubicin—hematologic cancer	6.77e-06	2.49e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Dexamethasone—hematologic cancer	6.73e-06	2.48e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Betamethasone—hematologic cancer	6.73e-06	2.48e-05	CcSEcCtD
Bortezomib—Dysgeusia—Epirubicin—hematologic cancer	6.73e-06	2.48e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Triamcinolone—hematologic cancer	6.68e-06	2.46e-05	CcSEcCtD
Bortezomib—Back pain—Epirubicin—hematologic cancer	6.64e-06	2.45e-05	CcSEcCtD
Bortezomib—Angiopathy—Doxorubicin—hematologic cancer	6.62e-06	2.44e-05	CcSEcCtD
Bortezomib—Malaise—Methotrexate—hematologic cancer	6.62e-06	2.44e-05	CcSEcCtD
Bortezomib—Dizziness—Etoposide—hematologic cancer	6.61e-06	2.43e-05	CcSEcCtD
Bortezomib—Muscle spasms—Epirubicin—hematologic cancer	6.6e-06	2.43e-05	CcSEcCtD
Bortezomib—Immune system disorder—Doxorubicin—hematologic cancer	6.6e-06	2.43e-05	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—hematologic cancer	6.6e-06	2.43e-05	CcSEcCtD
Bortezomib—Mediastinal disorder—Doxorubicin—hematologic cancer	6.58e-06	2.42e-05	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—hematologic cancer	6.57e-06	2.42e-05	CcSEcCtD
Bortezomib—Chills—Doxorubicin—hematologic cancer	6.55e-06	2.41e-05	CcSEcCtD
Bortezomib—Urticaria—Dexamethasone—hematologic cancer	6.54e-06	2.41e-05	CcSEcCtD
Bortezomib—Urticaria—Betamethasone—hematologic cancer	6.54e-06	2.41e-05	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Prednisone—hematologic cancer	6.53e-06	2.4e-05	CcSEcCtD
Bortezomib—Dizziness—Prednisolone—hematologic cancer	6.52e-06	2.4e-05	CcSEcCtD
Bortezomib—Arrhythmia—Doxorubicin—hematologic cancer	6.52e-06	2.4e-05	CcSEcCtD
Bortezomib—Asthenia—Triamcinolone—hematologic cancer	6.51e-06	2.4e-05	CcSEcCtD
Bortezomib—Abdominal pain—Dexamethasone—hematologic cancer	6.51e-06	2.4e-05	CcSEcCtD
Bortezomib—Body temperature increased—Betamethasone—hematologic cancer	6.51e-06	2.4e-05	CcSEcCtD
Bortezomib—Abdominal pain—Betamethasone—hematologic cancer	6.51e-06	2.4e-05	CcSEcCtD
Bortezomib—Body temperature increased—Dexamethasone—hematologic cancer	6.51e-06	2.4e-05	CcSEcCtD
Bortezomib—Nausea—Cisplatin—hematologic cancer	6.48e-06	2.39e-05	CcSEcCtD
Bortezomib—Insomnia—Prednisone—hematologic cancer	6.48e-06	2.39e-05	CcSEcCtD
Bortezomib—Vision blurred—Epirubicin—hematologic cancer	6.47e-06	2.38e-05	CcSEcCtD
Bortezomib—Paraesthesia—Prednisone—hematologic cancer	6.44e-06	2.37e-05	CcSEcCtD
Bortezomib—Pruritus—Triamcinolone—hematologic cancer	6.42e-06	2.36e-05	CcSEcCtD
Bortezomib—Cough—Methotrexate—hematologic cancer	6.41e-06	2.36e-05	CcSEcCtD
Bortezomib—Mental disorder—Doxorubicin—hematologic cancer	6.4e-06	2.35e-05	CcSEcCtD
Bortezomib—Ill-defined disorder—Epirubicin—hematologic cancer	6.37e-06	2.35e-05	CcSEcCtD
Bortezomib—Convulsion—Methotrexate—hematologic cancer	6.36e-06	2.34e-05	CcSEcCtD
Bortezomib—Vomiting—Etoposide—hematologic cancer	6.36e-06	2.34e-05	CcSEcCtD
Bortezomib—Malnutrition—Doxorubicin—hematologic cancer	6.36e-06	2.34e-05	CcSEcCtD
Bortezomib—Erythema—Doxorubicin—hematologic cancer	6.36e-06	2.34e-05	CcSEcCtD
Bortezomib—Anaemia—Epirubicin—hematologic cancer	6.35e-06	2.34e-05	CcSEcCtD
Bortezomib—Agitation—Epirubicin—hematologic cancer	6.31e-06	2.32e-05	CcSEcCtD
Bortezomib—Dyspepsia—Prednisone—hematologic cancer	6.31e-06	2.32e-05	CcSEcCtD
Bortezomib—Rash—Etoposide—hematologic cancer	6.31e-06	2.32e-05	CcSEcCtD
Bortezomib—Dermatitis—Etoposide—hematologic cancer	6.3e-06	2.32e-05	CcSEcCtD
Bortezomib—Headache—Etoposide—hematologic cancer	6.27e-06	2.31e-05	CcSEcCtD
Bortezomib—Flatulence—Doxorubicin—hematologic cancer	6.26e-06	2.31e-05	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—hematologic cancer	6.25e-06	2.3e-05	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—hematologic cancer	6.25e-06	2.3e-05	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—hematologic cancer	6.25e-06	2.3e-05	CcSEcCtD
Bortezomib—Decreased appetite—Prednisone—hematologic cancer	6.23e-06	2.29e-05	CcSEcCtD
Bortezomib—Dysgeusia—Doxorubicin—hematologic cancer	6.22e-06	2.29e-05	CcSEcCtD
Bortezomib—Rash—Prednisolone—hematologic cancer	6.22e-06	2.29e-05	CcSEcCtD
Bortezomib—Dermatitis—Prednisolone—hematologic cancer	6.21e-06	2.29e-05	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	6.21e-06	2.28e-05	CcSEcCtD
Bortezomib—Malaise—Epirubicin—hematologic cancer	6.19e-06	2.28e-05	CcSEcCtD
Bortezomib—Fatigue—Prednisone—hematologic cancer	6.18e-06	2.27e-05	CcSEcCtD
Bortezomib—Headache—Prednisolone—hematologic cancer	6.18e-06	2.27e-05	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—hematologic cancer	6.17e-06	2.27e-05	CcSEcCtD
Bortezomib—Vertigo—Epirubicin—hematologic cancer	6.17e-06	2.27e-05	CcSEcCtD
Bortezomib—Syncope—Epirubicin—hematologic cancer	6.16e-06	2.27e-05	CcSEcCtD
Bortezomib—Leukopenia—Epirubicin—hematologic cancer	6.15e-06	2.26e-05	CcSEcCtD
Bortezomib—Back pain—Doxorubicin—hematologic cancer	6.15e-06	2.26e-05	CcSEcCtD
Bortezomib—Constipation—Prednisone—hematologic cancer	6.13e-06	2.26e-05	CcSEcCtD
Bortezomib—Muscle spasms—Doxorubicin—hematologic cancer	6.11e-06	2.25e-05	CcSEcCtD
Bortezomib—Palpitations—Epirubicin—hematologic cancer	6.07e-06	2.23e-05	CcSEcCtD
Bortezomib—Confusional state—Methotrexate—hematologic cancer	6.04e-06	2.22e-05	CcSEcCtD
Bortezomib—Loss of consciousness—Epirubicin—hematologic cancer	6.04e-06	2.22e-05	CcSEcCtD
Bortezomib—Dizziness—Triamcinolone—hematologic cancer	6e-06	2.21e-05	CcSEcCtD
Bortezomib—Cough—Epirubicin—hematologic cancer	5.99e-06	2.21e-05	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—hematologic cancer	5.99e-06	2.21e-05	CcSEcCtD
Bortezomib—Vision blurred—Doxorubicin—hematologic cancer	5.99e-06	2.21e-05	CcSEcCtD
Bortezomib—Convulsion—Epirubicin—hematologic cancer	5.95e-06	2.19e-05	CcSEcCtD
Bortezomib—Infection—Methotrexate—hematologic cancer	5.95e-06	2.19e-05	CcSEcCtD
Bortezomib—Nausea—Etoposide—hematologic cancer	5.94e-06	2.19e-05	CcSEcCtD
Bortezomib—Hypertension—Epirubicin—hematologic cancer	5.93e-06	2.18e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Prednisone—hematologic cancer	5.91e-06	2.17e-05	CcSEcCtD
Bortezomib—Asthenia—Dexamethasone—hematologic cancer	5.91e-06	2.17e-05	CcSEcCtD
Bortezomib—Asthenia—Betamethasone—hematologic cancer	5.91e-06	2.17e-05	CcSEcCtD
Bortezomib—Ill-defined disorder—Doxorubicin—hematologic cancer	5.9e-06	2.17e-05	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—hematologic cancer	5.88e-06	2.16e-05	CcSEcCtD
Bortezomib—Anaemia—Doxorubicin—hematologic cancer	5.87e-06	2.16e-05	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—hematologic cancer	5.87e-06	2.16e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Prednisone—hematologic cancer	5.86e-06	2.16e-05	CcSEcCtD
Bortezomib—Nausea—Prednisolone—hematologic cancer	5.86e-06	2.16e-05	CcSEcCtD
Bortezomib—Myalgia—Epirubicin—hematologic cancer	5.85e-06	2.15e-05	CcSEcCtD
Bortezomib—Chest pain—Epirubicin—hematologic cancer	5.85e-06	2.15e-05	CcSEcCtD
Bortezomib—Arthralgia—Epirubicin—hematologic cancer	5.85e-06	2.15e-05	CcSEcCtD
Bortezomib—Agitation—Doxorubicin—hematologic cancer	5.84e-06	2.15e-05	CcSEcCtD
Bortezomib—Anxiety—Epirubicin—hematologic cancer	5.83e-06	2.15e-05	CcSEcCtD
Bortezomib—Pruritus—Betamethasone—hematologic cancer	5.82e-06	2.14e-05	CcSEcCtD
Bortezomib—Pruritus—Dexamethasone—hematologic cancer	5.82e-06	2.14e-05	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—hematologic cancer	5.82e-06	2.14e-05	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	5.81e-06	2.14e-05	CcSEcCtD
Bortezomib—Hyperhidrosis—Methotrexate—hematologic cancer	5.79e-06	2.13e-05	CcSEcCtD
Bortezomib—Discomfort—Epirubicin—hematologic cancer	5.78e-06	2.13e-05	CcSEcCtD
Bortezomib—Vomiting—Triamcinolone—hematologic cancer	5.77e-06	2.12e-05	CcSEcCtD
Bortezomib—Malaise—Doxorubicin—hematologic cancer	5.73e-06	2.11e-05	CcSEcCtD
Bortezomib—Rash—Triamcinolone—hematologic cancer	5.72e-06	2.11e-05	CcSEcCtD
Bortezomib—Dermatitis—Triamcinolone—hematologic cancer	5.71e-06	2.1e-05	CcSEcCtD
Bortezomib—Vertigo—Doxorubicin—hematologic cancer	5.71e-06	2.1e-05	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—hematologic cancer	5.71e-06	2.1e-05	CcSEcCtD
Bortezomib—Syncope—Doxorubicin—hematologic cancer	5.7e-06	2.1e-05	CcSEcCtD
Bortezomib—Urticaria—Prednisone—hematologic cancer	5.69e-06	2.1e-05	CcSEcCtD
Bortezomib—Leukopenia—Doxorubicin—hematologic cancer	5.69e-06	2.09e-05	CcSEcCtD
Bortezomib—Headache—Triamcinolone—hematologic cancer	5.68e-06	2.09e-05	CcSEcCtD
Bortezomib—Abdominal pain—Prednisone—hematologic cancer	5.67e-06	2.09e-05	CcSEcCtD
Bortezomib—Body temperature increased—Prednisone—hematologic cancer	5.67e-06	2.09e-05	CcSEcCtD
Bortezomib—Confusional state—Epirubicin—hematologic cancer	5.65e-06	2.08e-05	CcSEcCtD
Bortezomib—Diarrhoea—Dexamethasone—hematologic cancer	5.63e-06	2.07e-05	CcSEcCtD
Bortezomib—Diarrhoea—Betamethasone—hematologic cancer	5.63e-06	2.07e-05	CcSEcCtD
Bortezomib—Palpitations—Doxorubicin—hematologic cancer	5.62e-06	2.07e-05	CcSEcCtD
Bortezomib—Anaphylactic shock—Epirubicin—hematologic cancer	5.61e-06	2.06e-05	CcSEcCtD
Bortezomib—Oedema—Epirubicin—hematologic cancer	5.61e-06	2.06e-05	CcSEcCtD
Bortezomib—Hypotension—Methotrexate—hematologic cancer	5.6e-06	2.06e-05	CcSEcCtD
Bortezomib—Loss of consciousness—Doxorubicin—hematologic cancer	5.59e-06	2.06e-05	CcSEcCtD
Bortezomib—Infection—Epirubicin—hematologic cancer	5.57e-06	2.05e-05	CcSEcCtD
Bortezomib—Cough—Doxorubicin—hematologic cancer	5.55e-06	2.04e-05	CcSEcCtD
Bortezomib—Shock—Epirubicin—hematologic cancer	5.52e-06	2.03e-05	CcSEcCtD
Bortezomib—Convulsion—Doxorubicin—hematologic cancer	5.51e-06	2.03e-05	CcSEcCtD
Bortezomib—Nervous system disorder—Epirubicin—hematologic cancer	5.5e-06	2.02e-05	CcSEcCtD
Bortezomib—Thrombocytopenia—Epirubicin—hematologic cancer	5.49e-06	2.02e-05	CcSEcCtD
Bortezomib—Hypertension—Doxorubicin—hematologic cancer	5.49e-06	2.02e-05	CcSEcCtD
Bortezomib—Tachycardia—Epirubicin—hematologic cancer	5.47e-06	2.01e-05	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methotrexate—hematologic cancer	5.46e-06	2.01e-05	CcSEcCtD
Bortezomib—Skin disorder—Epirubicin—hematologic cancer	5.45e-06	2e-05	CcSEcCtD
Bortezomib—Dizziness—Dexamethasone—hematologic cancer	5.44e-06	2e-05	CcSEcCtD
Bortezomib—Dizziness—Betamethasone—hematologic cancer	5.44e-06	2e-05	CcSEcCtD
Bortezomib—Hyperhidrosis—Epirubicin—hematologic cancer	5.42e-06	2e-05	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—hematologic cancer	5.42e-06	1.99e-05	CcSEcCtD
Bortezomib—Myalgia—Doxorubicin—hematologic cancer	5.41e-06	1.99e-05	CcSEcCtD
Bortezomib—Chest pain—Doxorubicin—hematologic cancer	5.41e-06	1.99e-05	CcSEcCtD
Bortezomib—Arthralgia—Doxorubicin—hematologic cancer	5.41e-06	1.99e-05	CcSEcCtD
Bortezomib—Anxiety—Doxorubicin—hematologic cancer	5.39e-06	1.99e-05	CcSEcCtD
Bortezomib—Nausea—Triamcinolone—hematologic cancer	5.39e-06	1.98e-05	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—hematologic cancer	5.38e-06	1.98e-05	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	5.37e-06	1.98e-05	CcSEcCtD
Bortezomib—Discomfort—Doxorubicin—hematologic cancer	5.35e-06	1.97e-05	CcSEcCtD
Bortezomib—Anorexia—Epirubicin—hematologic cancer	5.34e-06	1.97e-05	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—hematologic cancer	5.34e-06	1.97e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Prednisone—hematologic cancer	5.28e-06	1.94e-05	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—hematologic cancer	5.27e-06	1.94e-05	CcSEcCtD
Bortezomib—Hypotension—Epirubicin—hematologic cancer	5.24e-06	1.93e-05	CcSEcCtD
Bortezomib—Vomiting—Dexamethasone—hematologic cancer	5.23e-06	1.93e-05	CcSEcCtD
Bortezomib—Vomiting—Betamethasone—hematologic cancer	5.23e-06	1.93e-05	CcSEcCtD
Bortezomib—Confusional state—Doxorubicin—hematologic cancer	5.23e-06	1.93e-05	CcSEcCtD
Bortezomib—Decreased appetite—Methotrexate—hematologic cancer	5.21e-06	1.92e-05	CcSEcCtD
Bortezomib—Rash—Dexamethasone—hematologic cancer	5.19e-06	1.91e-05	CcSEcCtD
Bortezomib—Rash—Betamethasone—hematologic cancer	5.19e-06	1.91e-05	CcSEcCtD
Bortezomib—Oedema—Doxorubicin—hematologic cancer	5.19e-06	1.91e-05	CcSEcCtD
Bortezomib—Anaphylactic shock—Doxorubicin—hematologic cancer	5.19e-06	1.91e-05	CcSEcCtD
Bortezomib—Dermatitis—Dexamethasone—hematologic cancer	5.19e-06	1.91e-05	CcSEcCtD
Bortezomib—Dermatitis—Betamethasone—hematologic cancer	5.19e-06	1.91e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—hematologic cancer	5.17e-06	1.9e-05	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—hematologic cancer	5.17e-06	1.9e-05	CcSEcCtD
Bortezomib—Headache—Betamethasone—hematologic cancer	5.16e-06	1.9e-05	CcSEcCtD
Bortezomib—Headache—Dexamethasone—hematologic cancer	5.16e-06	1.9e-05	CcSEcCtD
Bortezomib—Infection—Doxorubicin—hematologic cancer	5.15e-06	1.9e-05	CcSEcCtD
Bortezomib—Asthenia—Prednisone—hematologic cancer	5.14e-06	1.89e-05	CcSEcCtD
Bortezomib—Pain—Methotrexate—hematologic cancer	5.12e-06	1.89e-05	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Epirubicin—hematologic cancer	5.11e-06	1.88e-05	CcSEcCtD
Bortezomib—Shock—Doxorubicin—hematologic cancer	5.1e-06	1.88e-05	CcSEcCtD
Bortezomib—Nervous system disorder—Doxorubicin—hematologic cancer	5.09e-06	1.87e-05	CcSEcCtD
Bortezomib—Thrombocytopenia—Doxorubicin—hematologic cancer	5.08e-06	1.87e-05	CcSEcCtD
Bortezomib—Pruritus—Prednisone—hematologic cancer	5.07e-06	1.87e-05	CcSEcCtD
Bortezomib—Insomnia—Epirubicin—hematologic cancer	5.07e-06	1.87e-05	CcSEcCtD
Bortezomib—Tachycardia—Doxorubicin—hematologic cancer	5.06e-06	1.86e-05	CcSEcCtD
Bortezomib—Skin disorder—Doxorubicin—hematologic cancer	5.04e-06	1.85e-05	CcSEcCtD
Bortezomib—Paraesthesia—Epirubicin—hematologic cancer	5.03e-06	1.85e-05	CcSEcCtD
Bortezomib—Hyperhidrosis—Doxorubicin—hematologic cancer	5.01e-06	1.85e-05	CcSEcCtD
Bortezomib—Dyspnoea—Epirubicin—hematologic cancer	5e-06	1.84e-05	CcSEcCtD
Bortezomib—Anorexia—Doxorubicin—hematologic cancer	4.94e-06	1.82e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—hematologic cancer	4.94e-06	1.82e-05	CcSEcCtD
Bortezomib—Dyspepsia—Epirubicin—hematologic cancer	4.94e-06	1.82e-05	CcSEcCtD
Bortezomib—Diarrhoea—Prednisone—hematologic cancer	4.9e-06	1.81e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—hematologic cancer	4.9e-06	1.8e-05	CcSEcCtD
Bortezomib—Nausea—Dexamethasone—hematologic cancer	4.89e-06	1.8e-05	CcSEcCtD
Bortezomib—Nausea—Betamethasone—hematologic cancer	4.89e-06	1.8e-05	CcSEcCtD
Bortezomib—Decreased appetite—Epirubicin—hematologic cancer	4.87e-06	1.79e-05	CcSEcCtD
Bortezomib—Hypotension—Doxorubicin—hematologic cancer	4.85e-06	1.78e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.84e-06	1.78e-05	CcSEcCtD
Bortezomib—Fatigue—Epirubicin—hematologic cancer	4.83e-06	1.78e-05	CcSEcCtD
Bortezomib—Pain—Epirubicin—hematologic cancer	4.79e-06	1.76e-05	CcSEcCtD
Bortezomib—Constipation—Epirubicin—hematologic cancer	4.79e-06	1.76e-05	CcSEcCtD
Bortezomib—Urticaria—Methotrexate—hematologic cancer	4.76e-06	1.75e-05	CcSEcCtD
Bortezomib—Dizziness—Prednisone—hematologic cancer	4.74e-06	1.74e-05	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—hematologic cancer	4.74e-06	1.74e-05	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—hematologic cancer	4.74e-06	1.74e-05	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.73e-06	1.74e-05	CcSEcCtD
Bortezomib—Insomnia—Doxorubicin—hematologic cancer	4.69e-06	1.73e-05	CcSEcCtD
Bortezomib—Paraesthesia—Doxorubicin—hematologic cancer	4.66e-06	1.71e-05	CcSEcCtD
Bortezomib—Dyspnoea—Doxorubicin—hematologic cancer	4.62e-06	1.7e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Epirubicin—hematologic cancer	4.62e-06	1.7e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Epirubicin—hematologic cancer	4.58e-06	1.69e-05	CcSEcCtD
Bortezomib—Dyspepsia—Doxorubicin—hematologic cancer	4.57e-06	1.68e-05	CcSEcCtD
Bortezomib—Vomiting—Prednisone—hematologic cancer	4.56e-06	1.68e-05	CcSEcCtD
Bortezomib—Rash—Prednisone—hematologic cancer	4.52e-06	1.66e-05	CcSEcCtD
Bortezomib—Dermatitis—Prednisone—hematologic cancer	4.52e-06	1.66e-05	CcSEcCtD
Bortezomib—Decreased appetite—Doxorubicin—hematologic cancer	4.51e-06	1.66e-05	CcSEcCtD
Bortezomib—Headache—Prednisone—hematologic cancer	4.49e-06	1.65e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.48e-06	1.65e-05	CcSEcCtD
Bortezomib—Fatigue—Doxorubicin—hematologic cancer	4.47e-06	1.65e-05	CcSEcCtD
Bortezomib—Urticaria—Epirubicin—hematologic cancer	4.45e-06	1.64e-05	CcSEcCtD
Bortezomib—Pain—Doxorubicin—hematologic cancer	4.44e-06	1.63e-05	CcSEcCtD
Bortezomib—Constipation—Doxorubicin—hematologic cancer	4.44e-06	1.63e-05	CcSEcCtD
Bortezomib—Abdominal pain—Epirubicin—hematologic cancer	4.43e-06	1.63e-05	CcSEcCtD
Bortezomib—Body temperature increased—Epirubicin—hematologic cancer	4.43e-06	1.63e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—hematologic cancer	4.41e-06	1.62e-05	CcSEcCtD
Bortezomib—Asthenia—Methotrexate—hematologic cancer	4.3e-06	1.58e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Doxorubicin—hematologic cancer	4.27e-06	1.57e-05	CcSEcCtD
Bortezomib—Nausea—Prednisone—hematologic cancer	4.26e-06	1.57e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.24e-06	1.56e-05	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—hematologic cancer	4.24e-06	1.56e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Epirubicin—hematologic cancer	4.13e-06	1.52e-05	CcSEcCtD
Bortezomib—Urticaria—Doxorubicin—hematologic cancer	4.12e-06	1.52e-05	CcSEcCtD
Bortezomib—Abdominal pain—Doxorubicin—hematologic cancer	4.1e-06	1.51e-05	CcSEcCtD
Bortezomib—Body temperature increased—Doxorubicin—hematologic cancer	4.1e-06	1.51e-05	CcSEcCtD
Bortezomib—Diarrhoea—Methotrexate—hematologic cancer	4.1e-06	1.51e-05	CcSEcCtD
Bortezomib—Asthenia—Epirubicin—hematologic cancer	4.02e-06	1.48e-05	CcSEcCtD
Bortezomib—Pruritus—Epirubicin—hematologic cancer	3.97e-06	1.46e-05	CcSEcCtD
Bortezomib—Dizziness—Methotrexate—hematologic cancer	3.96e-06	1.46e-05	CcSEcCtD
Bortezomib—Diarrhoea—Epirubicin—hematologic cancer	3.84e-06	1.41e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Doxorubicin—hematologic cancer	3.82e-06	1.41e-05	CcSEcCtD
Bortezomib—Vomiting—Methotrexate—hematologic cancer	3.81e-06	1.4e-05	CcSEcCtD
Bortezomib—Rash—Methotrexate—hematologic cancer	3.78e-06	1.39e-05	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—hematologic cancer	3.77e-06	1.39e-05	CcSEcCtD
Bortezomib—Headache—Methotrexate—hematologic cancer	3.75e-06	1.38e-05	CcSEcCtD
Bortezomib—Asthenia—Doxorubicin—hematologic cancer	3.72e-06	1.37e-05	CcSEcCtD
Bortezomib—Dizziness—Epirubicin—hematologic cancer	3.71e-06	1.36e-05	CcSEcCtD
Bortezomib—Pruritus—Doxorubicin—hematologic cancer	3.67e-06	1.35e-05	CcSEcCtD
Bortezomib—Vomiting—Epirubicin—hematologic cancer	3.56e-06	1.31e-05	CcSEcCtD
Bortezomib—Nausea—Methotrexate—hematologic cancer	3.56e-06	1.31e-05	CcSEcCtD
Bortezomib—Diarrhoea—Doxorubicin—hematologic cancer	3.55e-06	1.31e-05	CcSEcCtD
Bortezomib—Rash—Epirubicin—hematologic cancer	3.53e-06	1.3e-05	CcSEcCtD
Bortezomib—Dermatitis—Epirubicin—hematologic cancer	3.53e-06	1.3e-05	CcSEcCtD
Bortezomib—Headache—Epirubicin—hematologic cancer	3.51e-06	1.29e-05	CcSEcCtD
Bortezomib—Dizziness—Doxorubicin—hematologic cancer	3.43e-06	1.26e-05	CcSEcCtD
Bortezomib—Nausea—Epirubicin—hematologic cancer	3.33e-06	1.23e-05	CcSEcCtD
Bortezomib—Vomiting—Doxorubicin—hematologic cancer	3.3e-06	1.21e-05	CcSEcCtD
Bortezomib—Rash—Doxorubicin—hematologic cancer	3.27e-06	1.2e-05	CcSEcCtD
Bortezomib—Dermatitis—Doxorubicin—hematologic cancer	3.27e-06	1.2e-05	CcSEcCtD
Bortezomib—Headache—Doxorubicin—hematologic cancer	3.25e-06	1.2e-05	CcSEcCtD
Bortezomib—Nausea—Doxorubicin—hematologic cancer	3.08e-06	1.13e-05	CcSEcCtD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—hematologic cancer	1.4e-06	8.37e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—IDH1—hematologic cancer	1.4e-06	8.37e-06	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AKT1—hematologic cancer	1.39e-06	8.35e-06	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—hematologic cancer	1.39e-06	8.35e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	1.39e-06	8.34e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTT1—hematologic cancer	1.39e-06	8.31e-06	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—hematologic cancer	1.39e-06	8.31e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTM1—hematologic cancer	1.38e-06	8.31e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NCOR1—hematologic cancer	1.38e-06	8.31e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—STAT3—hematologic cancer	1.38e-06	8.29e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—STAT3—hematologic cancer	1.38e-06	8.29e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—STAT3—hematologic cancer	1.38e-06	8.29e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTP1—hematologic cancer	1.38e-06	8.29e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.38e-06	8.28e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.38e-06	8.28e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TXN—hematologic cancer	1.38e-06	8.28e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NRAS—hematologic cancer	1.38e-06	8.27e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NRAS—hematologic cancer	1.38e-06	8.27e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NRAS—hematologic cancer	1.38e-06	8.27e-06	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—hematologic cancer	1.38e-06	8.27e-06	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—hematologic cancer	1.38e-06	8.27e-06	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—hematologic cancer	1.38e-06	8.27e-06	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—hematologic cancer	1.38e-06	8.27e-06	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—AKT1—hematologic cancer	1.38e-06	8.26e-06	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—AKT1—hematologic cancer	1.38e-06	8.26e-06	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—AKT1—hematologic cancer	1.38e-06	8.26e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—hematologic cancer	1.38e-06	8.26e-06	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—hematologic cancer	1.37e-06	8.22e-06	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—hematologic cancer	1.37e-06	8.22e-06	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—hematologic cancer	1.37e-06	8.22e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.36e-06	8.19e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—STAT3—hematologic cancer	1.36e-06	8.17e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NQO1—hematologic cancer	1.36e-06	8.16e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CD44—hematologic cancer	1.36e-06	8.16e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NRAS—hematologic cancer	1.36e-06	8.15e-06	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—hematologic cancer	1.36e-06	8.15e-06	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—hematologic cancer	1.36e-06	8.15e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SDC1—hematologic cancer	1.35e-06	8.13e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CREBBP—hematologic cancer	1.35e-06	8.12e-06	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—hematologic cancer	1.35e-06	8.1e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.35e-06	8.1e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NQO1—hematologic cancer	1.35e-06	8.09e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CD44—hematologic cancer	1.35e-06	8.09e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.34e-06	8.02e-06	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—hematologic cancer	1.33e-06	7.98e-06	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—hematologic cancer	1.32e-06	7.95e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK3—hematologic cancer	1.32e-06	7.92e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK3—hematologic cancer	1.32e-06	7.92e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK3—hematologic cancer	1.32e-06	7.92e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.32e-06	7.92e-06	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—hematologic cancer	1.32e-06	7.91e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ABCB1—hematologic cancer	1.31e-06	7.84e-06	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PIK3CA—hematologic cancer	1.3e-06	7.82e-06	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PIK3CA—hematologic cancer	1.3e-06	7.82e-06	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PIK3CA—hematologic cancer	1.3e-06	7.82e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK3—hematologic cancer	1.3e-06	7.81e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.3e-06	7.78e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.29e-06	7.76e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYCS—hematologic cancer	1.29e-06	7.72e-06	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PIK3CA—hematologic cancer	1.29e-06	7.71e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—hematologic cancer	1.28e-06	7.7e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—hematologic cancer	1.28e-06	7.7e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—hematologic cancer	1.28e-06	7.7e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CD—hematologic cancer	1.28e-06	7.7e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—hematologic cancer	1.28e-06	7.69e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—hematologic cancer	1.28e-06	7.69e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—hematologic cancer	1.28e-06	7.69e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	1.28e-06	7.67e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.28e-06	7.66e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYCS—hematologic cancer	1.28e-06	7.65e-06	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—hematologic cancer	1.27e-06	7.64e-06	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—hematologic cancer	1.27e-06	7.63e-06	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—hematologic cancer	1.27e-06	7.63e-06	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—hematologic cancer	1.27e-06	7.63e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTM1—hematologic cancer	1.27e-06	7.62e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NCOR1—hematologic cancer	1.27e-06	7.62e-06	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—hematologic cancer	1.27e-06	7.61e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	1.27e-06	7.6e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—hematologic cancer	1.27e-06	7.6e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—hematologic cancer	1.27e-06	7.6e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—hematologic cancer	1.26e-06	7.58e-06	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—hematologic cancer	1.26e-06	7.57e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.26e-06	7.57e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.26e-06	7.57e-06	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—hematologic cancer	1.25e-06	7.52e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.25e-06	7.5e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTP1—hematologic cancer	1.23e-06	7.4e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALOX5—hematologic cancer	1.23e-06	7.38e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MTHFR—hematologic cancer	1.22e-06	7.34e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.22e-06	7.33e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3R1—hematologic cancer	1.21e-06	7.27e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.19e-06	7.16e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NUP98—hematologic cancer	1.19e-06	7.14e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—hematologic cancer	1.19e-06	7.12e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—hematologic cancer	1.19e-06	7.12e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—hematologic cancer	1.19e-06	7.12e-06	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—hematologic cancer	1.18e-06	7.05e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—hematologic cancer	1.17e-06	7.02e-06	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—hematologic cancer	1.17e-06	7.02e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ABCB1—hematologic cancer	1.17e-06	7e-06	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—hematologic cancer	1.16e-06	6.98e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ADCY7—hematologic cancer	1.16e-06	6.94e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NCOA3—hematologic cancer	1.16e-06	6.94e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CD44—hematologic cancer	1.15e-06	6.91e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NQO1—hematologic cancer	1.15e-06	6.91e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NUP214—hematologic cancer	1.15e-06	6.89e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.14e-06	6.84e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTP1—hematologic cancer	1.13e-06	6.8e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NCOR1—hematologic cancer	1.13e-06	6.8e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTM1—hematologic cancer	1.13e-06	6.8e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.13e-06	6.77e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTR—hematologic cancer	1.12e-06	6.75e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.12e-06	6.75e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTP1—hematologic cancer	1.12e-06	6.74e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MTHFR—hematologic cancer	1.12e-06	6.73e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CB—hematologic cancer	1.12e-06	6.71e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ENO2—hematologic cancer	1.1e-06	6.62e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PIK3CA—hematologic cancer	1.09e-06	6.54e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PIK3CA—hematologic cancer	1.09e-06	6.54e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PIK3CA—hematologic cancer	1.09e-06	6.54e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYCS—hematologic cancer	1.09e-06	6.54e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.09e-06	6.53e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	1.08e-06	6.5e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.08e-06	6.47e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PIK3CA—hematologic cancer	1.07e-06	6.45e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ABCB1—hematologic cancer	1.07e-06	6.44e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.07e-06	6.42e-06	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—hematologic cancer	1.07e-06	6.39e-06	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—hematologic cancer	1.07e-06	6.39e-06	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—hematologic cancer	1.07e-06	6.39e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ABCB1—hematologic cancer	1.06e-06	6.38e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—hematologic cancer	1.05e-06	6.33e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—hematologic cancer	1.05e-06	6.33e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—hematologic cancer	1.05e-06	6.33e-06	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—hematologic cancer	1.05e-06	6.3e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SDC1—hematologic cancer	1.05e-06	6.27e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NCOR1—hematologic cancer	1.04e-06	6.25e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTM1—hematologic cancer	1.04e-06	6.25e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—hematologic cancer	1.04e-06	6.24e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTM1—hematologic cancer	1.03e-06	6.2e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NCOR1—hematologic cancer	1.03e-06	6.2e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CG—hematologic cancer	1.03e-06	6.17e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—hematologic cancer	1.01e-06	6.05e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—hematologic cancer	1.01e-06	6.05e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—hematologic cancer	1.01e-06	6.05e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MTHFR—hematologic cancer	1e-06	6.01e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—hematologic cancer	9.94e-07	5.97e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	9.89e-07	5.93e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	9.75e-07	5.85e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTEN—hematologic cancer	9.66e-07	5.8e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—hematologic cancer	9.65e-07	5.79e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—hematologic cancer	9.65e-07	5.79e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—hematologic cancer	9.65e-07	5.79e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTP1—hematologic cancer	9.61e-07	5.76e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CREBBP—hematologic cancer	9.53e-07	5.72e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—hematologic cancer	9.52e-07	5.71e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CG—hematologic cancer	9.43e-07	5.65e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	9.3e-07	5.58e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—EP300—hematologic cancer	9.21e-07	5.53e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MTHFR—hematologic cancer	9.21e-07	5.53e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MTHFR—hematologic cancer	9.13e-07	5.48e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ABCB1—hematologic cancer	9.09e-07	5.46e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CD—hematologic cancer	9.04e-07	5.42e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—hematologic cancer	8.92e-07	5.35e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—hematologic cancer	8.91e-07	5.34e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—hematologic cancer	8.91e-07	5.34e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—hematologic cancer	8.91e-07	5.34e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CD44—hematologic cancer	8.89e-07	5.33e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NQO1—hematologic cancer	8.89e-07	5.33e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTM1—hematologic cancer	8.83e-07	5.3e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NCOR1—hematologic cancer	8.83e-07	5.3e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.82e-07	5.29e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—hematologic cancer	8.78e-07	5.27e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CREBBP—hematologic cancer	8.74e-07	5.24e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3R1—hematologic cancer	8.53e-07	5.12e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CG—hematologic cancer	8.41e-07	5.05e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYCS—hematologic cancer	8.41e-07	5.05e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	8.36e-07	5.01e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CD—hematologic cancer	8.29e-07	4.97e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—hematologic cancer	8.18e-07	4.91e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.05e-07	4.83e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CB—hematologic cancer	7.88e-07	4.73e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3R1—hematologic cancer	7.82e-07	4.69e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MTHFR—hematologic cancer	7.8e-07	4.68e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CREBBP—hematologic cancer	7.8e-07	4.68e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CG—hematologic cancer	7.74e-07	4.64e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CG—hematologic cancer	7.67e-07	4.6e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTP1—hematologic cancer	7.41e-07	4.45e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CD—hematologic cancer	7.4e-07	4.44e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—hematologic cancer	7.3e-07	4.38e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CB—hematologic cancer	7.22e-07	4.33e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CREBBP—hematologic cancer	7.17e-07	4.3e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CREBBP—hematologic cancer	7.11e-07	4.27e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCB1—hematologic cancer	7.02e-07	4.21e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3R1—hematologic cancer	6.98e-07	4.19e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	6.88e-07	4.12e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CA—hematologic cancer	6.82e-07	4.09e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTM1—hematologic cancer	6.81e-07	4.09e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NCOR1—hematologic cancer	6.81e-07	4.09e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTEN—hematologic cancer	6.81e-07	4.08e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CD—hematologic cancer	6.8e-07	4.08e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CD—hematologic cancer	6.74e-07	4.05e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—hematologic cancer	6.72e-07	4.03e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—hematologic cancer	6.66e-07	3.99e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CG—hematologic cancer	6.56e-07	3.93e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—EP300—hematologic cancer	6.49e-07	3.89e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CB—hematologic cancer	6.45e-07	3.87e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3R1—hematologic cancer	6.42e-07	3.85e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3R1—hematologic cancer	6.37e-07	3.82e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTEN—hematologic cancer	6.24e-07	3.74e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CREBBP—hematologic cancer	6.08e-07	3.65e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTHFR—hematologic cancer	6.02e-07	3.61e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—EP300—hematologic cancer	5.95e-07	3.57e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CB—hematologic cancer	5.93e-07	3.56e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CB—hematologic cancer	5.88e-07	3.53e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CD—hematologic cancer	5.76e-07	3.46e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—hematologic cancer	5.69e-07	3.41e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTEN—hematologic cancer	5.57e-07	3.34e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—hematologic cancer	5.57e-07	3.34e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3R1—hematologic cancer	5.44e-07	3.26e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—EP300—hematologic cancer	5.31e-07	3.19e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTEN—hematologic cancer	5.12e-07	3.07e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTEN—hematologic cancer	5.08e-07	3.05e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	5.06e-07	3.04e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CB—hematologic cancer	5.02e-07	3.01e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—EP300—hematologic cancer	4.89e-07	2.93e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—EP300—hematologic cancer	4.84e-07	2.91e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CA—hematologic cancer	4.8e-07	2.88e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CREBBP—hematologic cancer	4.69e-07	2.81e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	4.45e-07	2.67e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CA—hematologic cancer	4.4e-07	2.64e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—hematologic cancer	4.39e-07	2.63e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTEN—hematologic cancer	4.34e-07	2.6e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	4.2e-07	2.52e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—EP300—hematologic cancer	4.14e-07	2.48e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CA—hematologic cancer	3.93e-07	2.36e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—hematologic cancer	3.92e-07	2.35e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	3.88e-07	2.33e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CA—hematologic cancer	3.61e-07	2.17e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—hematologic cancer	3.6e-07	2.16e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CA—hematologic cancer	3.58e-07	2.15e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTEN—hematologic cancer	3.35e-07	2.01e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—hematologic cancer	3.21e-07	1.93e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—EP300—hematologic cancer	3.19e-07	1.92e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CA—hematologic cancer	3.06e-07	1.84e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—hematologic cancer	2.95e-07	1.77e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—hematologic cancer	2.93e-07	1.76e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—hematologic cancer	2.5e-07	1.5e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	2.36e-07	1.42e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—hematologic cancer	1.93e-07	1.16e-06	CbGpPWpGaD
